CAJ | 학술논문

目的：探讨表皮生长因子受体（EGFR）基因第一内含子（CA）n 双核苷酸重复序列多态性与非小细胞肺癌（NSCLC）患者 EGFR 酪氨酸激酶抑制剂治疗敏感的相关性。方法用基因测序的方法检测了 NSCLC 患者274例肿瘤标本、13例血液标本 EGFR 基因第一内含子（CA）n 重复多态，并随访了其中76例患者 EGFR 酪氨酸激酶抑制剂治疗情况，统计学分析（CA）n 多态性与 EGFR - TKIs 治疗疗效的相关性。结果274例 NSCLC 患者中共检测到12种不同的（CA）n 重复多态，包含的 CA 重复序列数为9~23。118例（43.07%）患者为 CA 短重复（n≤16），156例（56.93%）为CA 长重复（n ﹥16）。13例 NSCLC 患者血液标本，5例（38.46%）为 CA 短重复（n≤16），8例（61.54%）为 CA 长重复（n
목적：탐토표피생장인자수체（EGFR）기인제일내함자（CA）n 쌍핵감산중복서렬다태성여비소세포폐암（NSCLC）환자 EGFR 락안산격매억제제치료민감적상관성。방법용기인측서적방법검측료 NSCLC 환자274례종류표본、13례혈액표본 EGFR 기인제일내함자（CA）n 중복다태，병수방료기중76례환자 EGFR 락안산격매억제제치료정황，통계학분석（CA）n 다태성여 EGFR - TKIs 치료료효적상관성。결과274례 NSCLC 환자중공검측도12충불동적（CA）n 중복다태，포함적 CA 중복서렬수위9~23。118례（43.07%）환자위 CA 단중복（n≤16），156례（56.93%）위CA 장중복（n ﹥16）。13례 NSCLC 환자혈액표본，5례（38.46%）위 CA 단중복（n≤16），8례（61.54%）위 CA 장중복（n
Objective To explore the association of(CA)n polymorphism in intron 1 of the EGFR gene with clinical outcome in patients with non small - cell lung cancer treated with EGFR TKIs. Methods CA repeat polymorphisms in intron 1 of EGFR from 274 tumor specimens of NSCLC patients and 13 peripheral blood samples as controls were analyzed by direct sequencing. 76 NSCLC patients treated with EGFR - TKIs were followed up to analyze the relation between(CA)n polymorphism in intron 1 of EGFR gene and clinical outcome. Results Twelve different (CA)n polymorphism were identified in the 274 patients,with the number of CA dinucleotide repeats ranging from 9 to 23. CA repeat was short (n≤16)in 118(43. 07% )and long(n ﹥ 16)in 156(56. 93% )patients. Disease control rate after EGFR - TKIs treatment was 80. 56% in pa-tients with short CA repeat,and 50% in patients with long CA repeat.(CA)n polymorphism was significantly correlated with the clinical response to EGFR - TKIs( P = 0. 005). Conclusion (CA)n polymorphism in intron 1 of the EGFR gene may be predictive for clinical response to EG-FR - TKIs in NSCLC patients.